https://orcid.org/0000-0003-1230-1591
References
- Thomas ED. Allogeneic bone marrow transplantation for blood cell disorders. Birth Defects Orig Artic Ser. 1982;18(7):361–369.
- Galimberti M, Polchi P, Lucarelli G, et al. Bone marrow transplantation in thalassemia after busulphan and cyclophosphamide. Report on 88 cases. Ann NY Acad Sci. 1987;511:464–467.
- Angelucci E, Baronciani D, Lucarelli G, et al. Bone marrow transplantation in class 3 thalassaemia patients. Bone Marrow Transplant. 1993;12(Suppl 1):63–64.
- Barrett AJ, Lucarelli G, Gale RP, et al. Bone marrow transplantation for thalassaemia--a preliminary report from the International Bone Marrow Transplant Registry. Prog Clin Biol Res. 1989;309:173–185.
- Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med. 1990;322(7):417–421.
- Delfini C, Polchi P, Izzi T, et al. Bone marrow donors other than HLA genotypically identical siblings for patients with thalassemia. Exp Hematol. 1985;13(11):1197–1200.
- Lucarelli G, Polchi P, Izzi T, et al. Marrow transplantation for thalassemia after treatment with busulfan and cyclophosphamide. Ann NY Acad Sci. 1985;445:428–431.
- Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in thalassemia. The experience of Pesaro. Prog Clin Biol Res. 1989;309:163–171.
- Sabloff M, Chandy M, Wang Z, et al. HLA-matched sibling bone marrow transplantation for β-thalassemia major. Blood. 2011;117(5):1745–1750.
- Pakakasama S, Hongeng S, Chaisiripoomkere W, et al. Allogeneic peripheral blood stem cell transplantation in children with homozygous beta-thalassemia and severe beta-thalassemia/hemoglobin E disease. J Pediatr Hematol Oncol. 2004;26(4):248–252.
- Hongeng S, Pakakasama S, Chuansumrit A, et al. Outcomes of transplantation with related- and unrelated-donor stem cells in children with severe thalassemia. Biol Blood Marrow Transplant. 2006;12(6):683–687.
- Anurathapan U, Hongeng S, Pakakasama S, et al. Hematopoietic stem cell transplantation for homozygous β-thalassemia and β-thalassemia/hemoglobin E patients from haploidentical donors. Bone Marrow Transplant. 2016;51(6):813–818.
- Anurathapan U, Pakakasama S, Rujkijyanont P, et al. Pretransplant immunosuppression followed by reduced-toxicity conditioning and stem cell transplantation in high-risk thalassemia: a safe approach to disease control. Biol Blood Marrow Transplant. 2013;19(8):1259–1262.
- Anurathapan U, Pakakasama S, Mekjaruskul P, et al. Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regimen according to a new risk stratification. Biol Blood Marrow Transplant. 2014;20(12):2066–2071.
- Russell JA, Tran HT, Quinlan D, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant. 2002;8(9):468–476.
- de Lima M, Couriel D, Thall PF, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004;104(3):857–864.
- Anurathapan U, Hongeng S, Pakakasama S, et al. Hematopoietic stem cell transplantation for severe thalassemia patients from haploidentical donors using a novel conditioning regimen. Biol Blood Marrow Transplant. 2020;26(6):1106–1112.